Skip to main content

Table 2 Predictors of TD. Univariable and multivariable Cox regression

From: Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

Variables

HR (95% CI)

p

aHR (95% CI)

p

Age (per 10 years more)

1.03 (0.91–1.15)

0.675

1.04 (0.91–1.19)

0.565

HIV risk factor:

 Heteosexual

Ref

 

Ref

 

 MSM

1.14 (0.87–1.50)

0.358

1.25 (0.93–1.68)

0.143

 IDUs

1.39 (0.93–2.08)

0.112

1.75 (1.13–2.70)

0.011

 Other

1.72 (0.24–12.38)

0.590

0.84 (0.11–6.73)

0.870

Previous regimen:

 2NRTI + bPI

Ref

 

Ref

 

 2NRTI + NNRTI

1.09 (0.65–1.81)

0.754

1.13 (0.66–1.93)

0.662

 2NRTI + InSTI

1.87 (1.21–2.90)

0.005

2.16 (1.30–3.60)

0.003

 Two-drug regimen

1.15 (0.79–1.67)

0.466

0.64 (0.37–1.10)

0.103

 Other

1.43 (0.79–2.59)

0.233

0.84 (0.41–1.71)

0.631

Switch from TDF-containing regimen

0.72 (0.54–0.95)

0.019

0.59 (0.39–0.88)

0.010

Reasons for switch to dual regimen:

 Simplification

Ref

 

Ref

 

 Dyslipidemia

0.71 (0.41–1.21)

0.207

0.74 (0.40–1.36)

0.332

 GI toxicity

1.04 (0.42–2.56)

0.929

1.12 (0.43–2.87)

0.820

 Liver toxicity

2.18 (1.14–4.16)

0.019

1.50 (0.71–3.17)

0.286

 Renal toxicity

1.17 (0.76–1.78)

0.475

1.14 (0.73–1.80)

0.565

 Bone toxicity

1.45 (0.60–3.62)

0.405

1.12 (0.3–2.91)

0.813

 CNS toxicity

1.21 (0.17–8.71)

0.849

1.94 (0.25–14.87)

0.524

 Other toxicity

2.98 (1.83–4.84)

< 0.001

2.16 (1.27–3.70)

0.005

 DDI

2.24 (0.71–7.09)

0.169

1.82 (0.54–6.12)

0.330

 Other

1.37 (0.84–2.25)

0.207

1.25 (0.74–2.13)

0.408

Time on previous regimen (per 1 year more)

0.98 (0.92–1.04)

0.547

0.92 (0.85–0.99)

0.021

eGFR at baseline (per 10 mL/min/1.73 m more)

1.06 (1.00–1.11)

0.039

1.05 (0.99–1.11)

0.102

Total cholesterol at baseline (per 10 mg/dL more)

1.03 (1.00–1.06)

0.058

1.04 (1.01–1.07)

0.012

Years on antiretroviral therapy

1.01 (0.99–1.03)

0.208

1.01 (0.99–1.04)

0.330

Study period:

 2008–2013

Ref

 

Ref

 

 2013–2014

2.04 (1.44–2.87)

< 0.001

1.98 (1.37–2.88)

< 0.001

 2014–2015

2.25 (1.47–3.43)

< 0.001

4.88 (3.00–7.94)

< 0.001

 2015–2017

2.18 (1.20–3.97)

< 0.001

8.45 (4.12–17.31)

< 0.001

Study treatment with Dolutegravir (versus bPIs)

0.50 (0.31–0.80)

0.004

0.15 (0.08–0.28)

< 0.001

  1. Note: bPI boosted protease inhibitor, TDF tenofovir, GI gastrointestinal, CNS central nervous system, DDI drug-drug interaction, eGFR estimated glomerular filtration rate
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us